Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

New Debt Facility

16 Sep 2020 07:00

RNS Number : 0964Z
KRM22 PLC
16 September 2020
 

KRM22 plc

 

("KRM22", the "Group" or the "Company")

 

New Debt Facility

 

 

KRM22 plc (AIM: KRM.L), the technology and software investment company, with a particular focus on risk management in capital markets, is pleased to announce that it has entered into an agreement for a new £3.0m convertible loan facility (the "Facility") arranged by Kestrel Partners LLP ("Kestrel"), the Company's largest shareholder. The Facility will be drawn down immediately on satisfaction of the conditions precedent set out in the loan agreement in a single tranche and will replace the Company's existing debt facility provided by Harbert European Growth Capital Fund II ("Harbert"). It is intended that the balance of the outstanding debt and charges of approximately £0.85m under the existing Harbert debt facility will be repaid early using the proceeds of the Facility.

 

The Facility is being provided to strengthen the Company's balance sheet and access to both working capital and growth capital in order to support the short to mid-term opportunities available to the Company.

 

The COVID-19 environment has reinforced the principle that companies need access to greater liquidity to address uncertainties and extending sales cycles, timing of contract signings and also to provide target customers with confidence in the financial strength of the Group.

 

Terms of the Facility

 

The Facility will be for a maximum of £3.0m and provided by funds managed by Kestrel Partners LLP. The Facility will be secured on certain Group assets and includes covenants based on the Group's financial performance, based on ARR, solvency and profitability and will also be guaranteed by certain members of the Group

 

The interest rate payable on debt drawn down is 9.5 per cent. per annum payable in cash quarterly in arrears and carries an arrangement fee of 2 per cent. payable on drawdown by deduction/ retention from the drawn proceeds. The term of the Facility is 3 years.

 

The Facility can be converted into new Ordinary Shares in the Company at any time at a conversion price of 38p and conversion can be requested by Kestrel at any time. The Company has the right to request conversion 18 months following the date of the agreement, subject to certain conditions regarding the Company's share price at that time. Kestrel has the right to prevent any conversion which would trigger a Rule 9 event under the Takeover Code.

 

The Kestrel Facility becoming effective and drawdown thereunder is conditional on the Company satisfying the conditions precedent set out in the agreement, including but not limited to the security for Harbert's existing facility being released and the security for Kestrel's Facility becoming effective.

 

Related Party Transaction

 

Kestrel is considered a "related party" as defined under the AIM Rules as a result of its substantial shareholding of 18.7 per cent. in the Company. The provision of the Facility by Kestrel constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules.

The Directors consider, having consulted with the Company's nominated adviser for the purposes of the AIM Rules, finnCap, that the terms of the Facility are fair and reasonable insofar as the Company's shareholders are concerned.

 

Keith Todd CBE, Executive Chairman and CEO commented:

 

"This Facility will support our current strategy and continued growth and will allow us to make small additional investments in critical resources and support our ongoing working capital requirements."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

 

For further information please contact:

 

KRM22 plc InvestorRelations@krm22.com

Keith Todd CBE, Executive Chairman and CEO

Kim Suter, CFO

 

finnCap Ltd (Nominated Adviser and Sole Broker) +44 (0)20 7220 0500

Carl Holmes / Kate Bannatyne / Matthew Radley

Alice Lane / Sunila de Silva (ECM)

 

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' regulatory, market, technology and operations risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimise risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 PLC is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODBCGDCGDBDGGU
Date   Source Headline
26th May 20263:24 pmRNSHolding(s) in Company
26th May 20262:25 pmRNSHolding(s) in Company
22nd May 20267:00 amRNSDirector Dealings
20th May 202611:19 amRNSDirector Dealings
20th May 20267:00 amRNSNotice of AGM and Posting of Annual Report
13th May 20267:00 amRNSFinal Results
29th Jan 20267:00 amRNSTrading Update
7th Jan 20267:00 amRNSAppointment of Director
20th Nov 20254:12 pmRNSTR-1
11th Nov 20257:00 amRNSIssue of Equity
10th Nov 20259:28 amRNSHolding(s) in Company
5th Nov 20251:05 pmRNSResult of GM
15th Oct 20257:00 amRNSResult of Placing
14th Oct 20254:50 pmRNSProposed Placing and Subscription
17th Sep 20257:00 amRNSInterim Results
7th Aug 20257:00 amRNSTrading Update
21st Jul 20257:00 amRNSIssue of Equity
27th Jun 20252:10 pmRNSResult of AGM
6th Jun 20257:00 amRNSDirector Dealing
2nd Jun 20257:00 amRNSIssue of Restricted Stock Units
30th May 20257:00 amRNSNotice of AGM and Posting of Annual Report
21st May 20257:00 amRNSDirector Dealing
19th May 20257:00 amRNSFinal Results
29th Apr 20257:00 amRNSFacility Amendment
7th Apr 20257:00 amRNSNew Customer Contracts
1st Apr 20257:00 amRNSFacility Amendment
18th Mar 20257:00 amRNSIssue of Equity
4th Mar 20257:00 amRNSNew Customer Contract
13th Feb 20255:00 pmRNSDirector Dealing
22nd Jan 20257:00 amRNSTrading Update
10th Jan 20257:00 amRNSIssue of Equity
23rd Dec 20247:00 amRNSLoan Facility Amendment
15th Oct 20247:00 amRNSIssue of Equity
25th Sep 20247:00 amRNSInterim Results
3rd Sep 20247:00 amRNSChange of Registered Office
29th Aug 20247:00 amRNSNew Customer Contract
22nd Aug 202410:00 amRNSGrant of Options and Director/PDMR Shareholding
19th Aug 20247:00 amRNSIssue of Equity
18th Jul 20247:00 amRNSHalf Year Trading Update
21st Jun 202412:49 pmRNSResult of AGM
29th May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.